RT Journal Article
T1 Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
A1 Herrero-Fernandez, Ines
A1 Pacheco, Yolanda M.
A1 Genebat, Miguel
A1 Rodriguez-Mendez, Maria del Mar
A1 Lozano, Maria del Carmen
A1 Polaino, Maria Jose
A1 Rosado-Sanchez, Isaac
A1 Tarancon-Diez, Laura
A1 Munoz-Fernandez, Maria Angeles
A1 Ruiz-Mateos, Ezequiel
A1 Leal, Manuel
K1 maraviroc
K1 vaccine
K1 HIV infection
K1 combined antiretroviral treatment
K1 hepatitis A virus
K1 hepatitis B virus
K1 Hiv-infected patients
K1 Immune-responses
K1 High-rates
K1 Nonresponders
K1 Adults
K1 Immunosenescence
K1 Progression
K1 Blockade
K1 Efficacy
AB The response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine. Fifty-seven patients on suppressor cART were administered the HBV vaccine. The final response, the early response, and the maintenance of the response were assessed. An anti-HBs titer of >10 mIU/ml was considered a positive response. A subgroup of subjects was simultaneously vaccinated against hepatitis A virus (HAV). Lineal regression analyses were performed to determine demographic, clinical, and immunological factors associated with the anti-HBs titer. Vaccine response was achieved in 90% of the subjects. After 1 year, 81% maintained protective titers. Only simultaneous HAV vaccination was independently associated with the magnitude of the response in anti-HBs titers, with a P value of 0.045 and a regression coefficient (B) [95% confident interval (CI)] of 236 [5 to 468]. In subjects ≤50 years old (n = 42), MVC-cART was independently associated with the magnitude of the response (P = 0.009; B [95% CI], 297 [79 to 516]) together with previous vaccination and simultaneous HAV vaccination. High rates of HBV vaccine response can be achieved by revaccination, simultaneous HAV vaccination, and administration of cARTs including MVC. MVC may be considered for future vaccination protocols in patients on suppressive cART.
PB American Society for Microbiology
SN 0066-4804
YR 2018
FD 2018-01-01
LK http://hdl.handle.net/10668/19009
UL http://hdl.handle.net/10668/19009
LA en
NO Herrero-Fernández I, Pacheco YM, Genebat M, Rodriguez-Méndez MDM, Lozano MDC, Polaino MJ, et al. Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e02050-17.
NO This study was funded by an investigator-initiated research grant from ViiV Healthcare S.L. (grant number 205644) and by grants from the Fondo de Investigación Sanitaria (FIS; PI14/01693; PI16/01863), cofunded by Fondos Europeos para el Desarrollo Regional (FEDER) and the Junta de Andalucía, Consejería de Economía, Innovación, Ciencia y Empleo (Proyecto de Investigación de Excelencia; CTS2593). The Spanish AIDS Research Network of Excellence also supported this study (RD16/0025/0019). E.R.-M. and Y.M.P. were supported by the Fondo de Investigación Sanitaria through the ‘Miguel Servet’ programs (CPII014/00025 and CPII13/00037, respectively). Y.M.P. was supported by the Consejería de Salud y Bienestar Social of Junta de Andalucía through the ‘Nicolás Monardes’ program (C-0010/13). L.T.-D. was supported by Instituto de Salud Carlos III (PFIS program; FI00/00431). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.We express our most sincere thanks to all the subjects included in the study and to HIV Biobank of the Spanish AIDS Research Network. We thank also Magdalena Rodriguez and Marien Gutierrez Sancho for their assistance at the Day Care Hospital (Infectious Diseases Department), to Antonia Abad and Marta de Luna for their technical assistance, and to Juan Manuel Praena for statistical assistance.
DS RISalud
RD Apr 8, 2025